Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 plus paclitaxel-carboplatin as neoadjuvant therapy in advanced high-grade serous ovarian cancer
ChiCTR2500109912Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of QL1706 in High-Grade Serous Ovarian Cancer (HGSOC), sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoints: R0 resection rate and Progression-free survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
QL1706
03
Conditions
High-Grade Serous Ovarian Cancer (HGSOC)
Beyond the preview
Go deeper on ChiCTR2500109912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109912.